• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CVS Health (CVS), What Is Behind The Fresh Attention?

    Simply Wall St·10/25/2026 19:27:15
    語音播報

    CVS Health (CVS) is back in focus after launching its Health100 AI platform, expanding GLP 1 programs, and reporting improved Q2 2026 profitability, while also resolving a US$315 million opioid related legal case.

    Recent attention on CVS Health has come alongside a share price that is up 16.65% year to date and a 1 year total shareholder return of 17.59%, even though the stock declined 12.70% over the past 90 days. That combination suggests investors have warmed to the Health100 AI launch, GLP 1 expansion and legal overhang relief earlier in the year. The recent pullback may reflect a reset in expectations after strong multi year total shareholder returns of 57.89% over 3 years and 23.75% over 5 years at a last close of US$93.47.

    Scan 29 high quality undervalued stocks hand picked for investors watching how CVS Health blends AI, GLP 1 exposure and legal clean up into a broader hunt for mispriced healthcare platforms.

    CVS Health now sits at an interesting crossroads after a strong year to date and a sharp 90 day pullback. Should that reset be treated as a potential entry point, or as a reason to keep waiting for cheaper terms?

    Most Popular Narrative: 25% Undervalued

    On the most followed narrative, CVS Health screens as undervalued, with a fair value of $124 against the last close of $93.47, which puts the current pullback in a different light for anyone focused on long term earnings power.

    CVS Health is no longer the broken-Aetna-plus-drugstore story the market used for most of 2024–25. Through the first half of 2026 the company has raised full-year guidance twice, Aetna’s medical benefit ratio has improved, cash flow is running well ahead of plan, and all three operating segments are growing. The stock still trades as if the insurance rebuild is temporary and the PBM is about to be regulated into irrelevance.

    See why 5 investors see CVS Health as 25% undervalued.

    According to andrei9868, who sets that $124 narrative fair value, the key hinge is whether Aetna’s margin gains and cash generation hold through 2027 while the Health Services and Pharmacy & Consumer Wellness units keep contributing profit at scale. The view in that storyline is that the market still prices CVS Health like a fragile insurer, even though management is guiding to at least $8.44 of adjusted EPS in 2027 and has already lifted 2026 guidance on revenue, operating income and cash from operations.

    On those assumptions, the narrative frames CVS Health as undervalued, because the current share price implies a lower multiple on that earnings base than the author believes is warranted for a vertically integrated healthcare group generating more than $11.5b of cash from operations. The flip side in that same thesis is clear as well, since a weaker medical benefit ratio, pressure on pharmacy margins or heavier PBM reform would challenge both the $8.00 of 2026 EPS and the 2027 floor that anchor the $124 estimate.

    Result: Fair Value of $124 (UNDERVALUED)

    Still, this storyline can break if Aetna’s medical cost trend turns higher again or if pharmacy benefit reforms compress Health Services profitability faster than expected.

    Find out about the key risks to this CVS Health narrative.

    Next Steps

    If the mixed sentiment in this CVS Health story has you uncertain, take action promptly and evaluate both sides for yourself using the 4 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond CVS Health?

    If CVS Health has your attention, do not stop here. Broaden your watchlist with fresh ideas built from hard numbers, not headlines.